Buy Day today: Neutral (53) Mixed market breadth · no major macro event

Xeris Pharmaceuticals Inc (XERS)

Healthcare Drug Manufacturers - Specialty & Generic

8.10 $

-4.0% vs. previous close

Closing price · As of: 31. Jul 2026

Xeris Pharmaceuticals Inc (XERS) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q1 26), "Total Assets" came in at 392 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow

Annual Quarterly

All figures in millions of USD.

Balance Sheet XERS
Tick rows to compare them in a chart (up to 4)	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26
Total Assets	329	328	323	337	332	321	323	315	335	370	384	392
Current Assets	156	158	156	173	170	163	168	163	186	224	240	252
Cash	46	46	67	63	58	59	72	58	59	92	111	112
Cash & Short-Term Investments	81	66	72	87	78	69	72	58	59	92	111	112
Receivables	30	46	39	37	42	41	40	46	53	54	51	56
Inventory	37	38	39	41	43	45	48	53	67	67	69	74
Property, Plant & Equipment	30	30	–	–	–	–	–	–	–	–	–	–
Goodwill	23	23	23	23	23	23	23	23	23	23	23	23
Intangible Assets	115	112	110	107	104	102	99	96	94	91	88	85
Total Liabilities	315	324	329	346	351	349	353	351	354	371	370	379
Current Liabilities	80	87	95	73	75	91	100	95	95	116	110	119
Short-Term Debt	1.9	2.4	3.5	4.6	5.3	21	21	18	6.2	6.2	6.2	6.3
Accounts Payable	12	12	12	7.1	5.8	7.5	2.3	6.4	9.5	6.5	3.1	11
Long-Term Debt	188	190	191	230	230	216	217	218	219	219	220	221
Shareholders' Equity	14	3.9	-6.8	-9.2	-19	-28	-30	-35	-19	-0.9	14	13
Retained Earnings	-591	-604	-617	-636	-651	-667	-672	-681	-683	-682	-671	-669
Shares Outstanding	137	138	138	141	148	149	149	152	156	178	180	178

Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Cookie settings